US Stock Insider Trading | Futai Pharmaceutical Discloses 15 Insider Transactions on February 12

K-LinePoet · 2026-03-05T13:36:18+00:00

On February 12, 2026, Futai Pharmaceutical (VRTX) disclosed 15 insider trading transactions. Director Kewalramani Reshma sold 8,297 shares on February 11, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 12, 2026 | Executive | Tatsis Ourania | February 10, 2026 | Sell | 2,140 | 468.41 | 1,002,400 || February |

K-LinePoet

2026-03-05 13:36:18

On February 12, 2026, Vertex Pharmaceuticals (VRTX) disclosed 15 insider transactions. Director Reshma Kewalramani sold 8,297 shares on February 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 12, 2026	Executive	Ourania Tatsis	February 10, 2026	Sell	2,140	468.41	$1,002,400
February 12, 2026	Executive	Duncan McKechnie	February 10, 2026	Sell	1,127	468.41	$527,900
February 12, 2026	Executive	Ourania Tatsis	February 11, 2026	Sell	466	460.43	$21,460
February 12, 2026	Director	Reshma Kewalramani	February 10, 2026	Sell	8,297	468.41	$3,886,400
February 12, 2026	Executive	Jonathan Biller	February 10, 2026	Sell	1,630	468.41	$763,500
February 12, 2026	Executive	Carmen Bozic	February 10, 2026	Sell	2,145	468.41	$1,004,700
February 12, 2026	Executive	Amit Sachdev	February 10, 2026	Sell	2,057	468.41	$963,500
February 12, 2026	Executive	Jonathan Biller	February 11, 2026	Sell	1,925	460.43	$886,300
February 12, 2026	Executive	Mark E. Bunnage	February 10, 2026	Sell	1,127	468.41	$527,900
February 12, 2026	Executive	Mark E. Bunnage	February 11, 2026	Sell	2,021	460.43	$930,500

[Company Information]

Vertex Pharmaceuticals Incorporated, founded in 1989, is a global biotechnology company. The company focuses on discovering, developing, manufacturing, and commercializing small-molecule drugs for serious diseases in specialized markets. It collaborates with some of the world’s largest pharmaceutical companies, leading non-profit disease research institutions, and many of the most renowned academic institutions worldwide. The company has two products: KALYDECO and INCIVEK.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.